Pacira (PCRX) BioSciences announced updated three-year results and a new subset analyses demonstrating sustained efficacy and safety across all patient subgroups, including varying disease severities, from its open-label Phase 1 clinical trial evaluating PCRX-201, a novel gene therapy candidate for osteoarthritis of the knee. Results show that a single intra-articular injection of PCRX-201 at each of the three doses tested was well tolerated and produced sustained improvements in pain, stiffness, and function through 156 weeks in patients with osteoarthritis of the knee.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira (PCRX) Q3 Earnings Cheat Sheet
- Pacira’s Pediatric Analgesia Study: A Potential Game-Changer for Postoperative Pain Management
- Pacira’s Innovative Study on Knee OA Pain Management: What Investors Need to Know
- Pacira’s Phase 2 Study: A New Approach to Hip Osteoarthritis Treatment
- Pacira’s New Osteoarthritis Treatment: A Promising Clinical Study Update